These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1709545)

  • 1. Prospective study on the hepatitis safety of intravenous immunoglobulin, pH 4.25.
    Rousell RH; Budinger MD; Pirofsky B; Schiff RI
    Vox Sang; 1991; 60(2):65-8. PubMed ID: 1709545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-A non-B hepatitis and the safety of intravenous immune globulin, pH 4.2: a retrospective survey. Preliminary communication.
    Rousell RH; Good RA; Pirofsky B; Schiff RI
    Vox Sang; 1988; 54(1):6-13. PubMed ID: 3126601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Liver function tests, hepatitis A, B, C markers and HIV antibodies in patients with Basedow's ophthalmopathy treated with intravenous immunoglobulins].
    Antonelli A; Neri S; Gasperini L; Alberti B; Saracino A; Gambuzza C; Agostini S; Baschieri L
    Clin Ter; 1992 Sep; 141(9 Pt 2):55-61. PubMed ID: 1468200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of HTLV-III/LAV seroconversion and non-A, non-B hepatitis in recipients of plasma products.
    Piszkiewicz D; Kingdon H; Lee ML; Hooper J
    Dev Biol Stand; 1987; 67():327-31. PubMed ID: 2440745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis.
    Imbach P; Perret BA; Babington R; Kaminski K; Morell A; Heiniger HJ
    Vox Sang; 1991; 61(4):240-3. PubMed ID: 1776240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin.
    Williams PE; Yap PL; Gillon J; Crawford RJ; Urbaniak SJ; Galea G
    Vox Sang; 1989; 57(1):15-8. PubMed ID: 2508325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
    Pirofsky B
    Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data.
    Yap PL
    Clin Ther; 1996; 18 Suppl B():43-58. PubMed ID: 8930441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum ALT levels in patients with primary hypogammaglobulinaemia receiving replacement therapy with intravenous immunoglobulin or fresh frozen plasma.
    Leen CL; Yap PL; Neill G; McClelland DB; Westwood A
    Vox Sang; 1986; 50(1):26-32. PubMed ID: 3082075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The safety of treatment with intravenous gamma-globulin in patients with primary hypogammaglobulinemias].
    Sierra FJ; Gil A; Lavilla P; Martín JC
    Med Clin (Barc); 1995 Nov; 105(16):636. PubMed ID: 8523946
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study.
    Bresee JS; Mast EE; Coleman PJ; Baron MJ; Schonberger LB; Alter MJ; Jonas MM; Yu MY; Renzi PM; Schneider LC
    JAMA; 1996 Nov; 276(19):1563-7. PubMed ID: 8918853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of intravenous immunoglobulins in polymyositis and dermatomyositis. An open trial in 15 patients].
    Cherin P; Herson S; Wechsler B; Piette JC; Bletry O; Degennes C; Ziza JM; Du LT; Godeau P
    Presse Med; 1991 Feb; 20(6):244-9. PubMed ID: 1706860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses to hepatitis C virus and its modes of transmission in dialysis patients.
    Almroth G; Ekermo B; Franzén L; Hed J
    Nephron; 1991; 59(2):232-5. PubMed ID: 1659671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of intravenous pH 4.0 treated gamma globulin in humoral immunodeficiency disease.
    Cunningham-Rundles C; Smithwick EM; Siegal FP; Day NK; Lion A; O'Malley J; Barandun S; Good RA
    Birth Defects Orig Artic Ser; 1983; 19(3):201-3. PubMed ID: 6197105
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of intravenous immunoglobulin treatment.
    Atrah HI; Crawford RJ; Dow BC; Mitchell R
    J Clin Pathol; 1985 Oct; 38(10):1192-3. PubMed ID: 3932489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1994 Jul; 43(28):505-9. PubMed ID: 8022396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-A, non-B hepatitis after intravenous gammaglobulin.
    Lever AM; Webster AD; Brown D; Thomas HC
    Lancet; 1985 Mar; 1(8428):587. PubMed ID: 2579302
    [No Abstract]   [Full Text] [Related]  

  • 18. The serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase ratio as a prognostic index in severe acute viral hepatitis.
    Gitlin N
    Am J Gastroenterol; 1982 Jan; 77(1):2-4. PubMed ID: 6801971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-A, non-B hepatitis after intravenous gammaglobulin.
    Lancet; 1986 Feb; 1(8476):322-3. PubMed ID: 2418320
    [No Abstract]   [Full Text] [Related]  

  • 20. Low incidence of non-A, non-B post-transfusion hepatitis in London confirmed by hepatitis C virus serology.
    Contreras M; Barbara JA; Anderson CC; Ranasinghe E; Moore C; Brennan MT; Howell DR; Aloysius S; Yardumian A
    Lancet; 1991 Mar; 337(8744):753-7. PubMed ID: 1672391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.